GNRH1 and adenocarcinoma: The CP336 PDX model was established from a lymph node biopsy containing adenocarcinoma with small-cell differentiation (ICR/RMH 181) and was taken from a patient with mCRPC previously exposed to luteinizing hormone–releasing hormone (LHRH) analog, bicalutamide, and abiraterone (Figure 8, A and B).